menu
    • menu
    [{"orgOrder":0,"company":"Phebra","sponsor":"BioSenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2024","type":"Agreement","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Phebra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phebra \/ BioSenic","highestDevelopmentStatusID":"4","companyTruncated":"Phebra \/ BioSenic"},{"orgOrder":0,"company":"BioSenic","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Financing","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioSenic \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ ABO Securities"},{"orgOrder":0,"company":"BioSenic","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Agreement","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ ABO Securities"},{"orgOrder":0,"company":"BioSenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Phebra","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Phebra"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Gestys Sant\u00e9 Biotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Gestys Sant\u00e9 Biotech","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Gestys Sant\u00e9 Biotech"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||RAR-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"Medsenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||RAR-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Medsenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2022","type":"Acquisition","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bone Therapeutics \/ Medsenic","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Medsenic"},{"orgOrder":0,"company":"Medsenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Inapplicable"},{"orgOrder":0,"company":"Orsenix","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Acquisition","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Orsenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orsenix \/ Syros Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Orsenix \/ Syros Pharmaceuticals"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"Australasian Leukaemia and Lymphoma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Australasian Leukaemia and Lymphoma Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Australasian Leukaemia and Lymphoma Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Australasian Leukaemia and Lymphoma Group \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Phebra"},{"orgOrder":0,"company":"Medsenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Neurology","graph2":"Preclinical","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medsenic \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medsenic \/ Inapplicable"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2021","type":"Partnership","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Phebra"}]

    Find Clinical Drug Pipeline Developments & Deals for Arsenic Trioxide

    Menu

    Arsenic Trioxide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    BioSenic

    Belgium arrow
    Immuno-Oncology 360
    Not Confirmed

    BioSenic

    Belgium arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    BioSenic Releases New Analysis of Phase 2 Data for Arsenic Trioxide in cGvHD

    Details : Arscimed (arsenic trioxide) is a thioredoxin reductase 1 inhibitor small molecule drug candidate, which is being evaluated for the treatment of chronic graft versus host disease.

    Product Name : Arscimed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    July 18, 2024

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    BioSenic

    Belgium arrow
    Immuno-Oncology 360
    Not Confirmed

    BioSenic

    Belgium arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Study Phase : Phase II

    Sponsor : Phebra

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Medsenic Subsidiary Signs Licensing Agreement with Phebra PTY Ltd

    Details : Medsenic and Phebra should facilitate the final steps of manufacturing, clinical confirmation of efficacy and subsequent commercialization of oral ArsciCor (arsenic trioxide) in cGvHD.

    Product Name : ArsciCor

    Product Type : Cytotoxic Drug

    Upfront Cash : Undisclosed

    July 02, 2024

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Highest Development Status : Phase II

    Sponsor : Phebra

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    BioSenic

    Belgium arrow
    Immuno-Oncology 360
    Not Confirmed

    BioSenic

    Belgium arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Study Phase : Phase II

    Sponsor : ABO Securities

    Deal Size : $2.2 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    BioSenic Signs a New Subscription Agreement for a Maximum of EUR 2.1M in Convertible Bonds

    Details : The proceeds of the financing will essentially contribute to continuing to advance the clinical development of Arscimed (arsenic trioxide) in the treatment of chronic graft versus host disease.

    Product Name : Arscimed

    Product Type : Cytotoxic Drug

    Upfront Cash : Undisclosed

    June 21, 2024

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Highest Development Status : Phase II

    Sponsor : ABO Securities

    Deal Size : $2.2 million

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    BioSenic

    Belgium arrow
    Immuno-Oncology 360
    Not Confirmed

    BioSenic

    Belgium arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Study Phase : Preclinical

    Sponsor : Gestys Santé Biotech

    Deal Size : $0.5 million

    Deal Type : Private Placement

    DEALS_DEV arrow-down

    BioSenic Raises €500,000 in Private Placement of New Shares with Established New Investors

    Details : BioSenic will use proceeds for a Phase 3 trial with Arscimed (oral arsenic trioxide) for first-line treatment of chronic graft-versus-host disease.

    Product Name : Arscimed

    Product Type : Cytotoxic Drug

    Upfront Cash : Undisclosed

    February 02, 2024

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Highest Development Status : Preclinical

    Sponsor : Gestys Santé Biotech

    Deal Size : $0.5 million

    Deal Type : Private Placement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Phebra

    Australia arrow
    Cancer Research
    Not Confirmed

    Phebra

    Australia arrow
    Cancer Research
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Study Phase : Preclinical

    Sponsor : BioSenic

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    BioSenic Reaches Agreement with Phebra on Oral Arsenic Trioxide Development for cGvHD

    Details : The agreement aims for the development of the first oral formulation of ArsciCor (arsenic troxide) in the field of several targeted autoimmune diseases, including for cGvHD treatment.

    Product Name : ArsciCor

    Product Type : Cytotoxic Drug

    Upfront Cash : Undisclosed

    January 15, 2024

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Highest Development Status : Preclinical

    Sponsor : BioSenic

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    BioSenic

    Belgium arrow
    Immuno-Oncology 360
    Not Confirmed

    BioSenic

    Belgium arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Study Phase : Phase II

    Sponsor : ABO Securities

    Deal Size : Undisclosed

    Deal Type : Financing

    DEALS_DEV arrow-down

    BioSenic Signs a New Subscription Agreement for a Maximum of EUR 1.2M in Convertible Bonds

    Details : The proceeds from the financing will contribute to advancing clinical development of BioSenic’s lead asset its ATO product, Arscimed (arsenic trioxide), for treating chronic graft versus host disease.

    Product Name : Arscimed

    Product Type : Cytotoxic Drug

    Upfront Cash : Undisclosed

    January 08, 2024

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Highest Development Status : Phase II

    Sponsor : ABO Securities

    Deal Size : Undisclosed

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    BioSenic

    Belgium arrow
    Immuno-Oncology 360
    Not Confirmed

    BioSenic

    Belgium arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Biosenic Performs Further Analysis of its Phase 2 Clinical Trial Data, Leading to an Optimal Administration Sc...

    Details : ATO (arsenic trioxide) is administered daily by IV infusions, which is investigated for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious disease.

    Product Name : ArsciCor

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    September 27, 2023

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Medsenic

    France arrow
    Immuno-Oncology 360
    Not Confirmed

    Medsenic

    France arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Study Phase : Undisclosed

    Sponsor : Phebra

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Biosenic Provides Update Regarding Current License Agreement With Phebra

    Details : Under the license agreement, Medsenic agreed to commence a clinical study using Phebra's oral formulation OATO (arsenic trioxide) for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious diseases.

    Product Name : ArsciCor

    Product Type : Cytotoxic Drug

    Upfront Cash : Undisclosed

    May 29, 2023

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Highest Development Status : Undisclosed

    Sponsor : Phebra

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    BioSenic

    Belgium arrow
    Immuno-Oncology 360
    Not Confirmed

    BioSenic

    Belgium arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Arsenic Trioxide,Metal ion

    Therapeutic Area : Immunology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    BioSenic Receives Key European Patent From EPO, For Further Therapeutic Development in Cancer, Infectious and ...

    Details : Arscimed® (arsenic trioxide), is a able to radically modify the autoimmune cascade and normalise the immune system without causing nonspecific immunosuppressionbeing studied for cGvHD.

    Product Name : Arscimed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    April 18, 2023

    Lead Product(s) : Arsenic Trioxide,Metal ion

    Therapeutic Area : Immunology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    BioSenic

    Belgium arrow
    Immuno-Oncology 360
    Not Confirmed

    BioSenic

    Belgium arrow
    Immuno-Oncology 360
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    BioSenic SA Provides Update On Its Autoimmune Disease Platform Based On ATO (arsenic trioxide)

    Details : The BioSenic autoimmune platform has been constructed to target systemic autoimmune diseases using arsenic trioxide (Arscimed, ATO). This uses ATO’s first-in-class mechanism of action as an active anti-inflammatory and immunomodulatory agent.

    Product Name : Arscimed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    November 08, 2022

    Lead Product(s) : Arsenic Trioxide

    Therapeutic Area : Immunology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth